Canaccord Genuity Reiterates a 'Buy' on ArthroCare (ARTC); Second Legal Overhang Removed, Only DOJ Remains; Expect Stock to Trade Up

Canaccord Genuity reiterates a 'Buy' on ArthroCare (NASDAQ: ARTC) price target of $43.50.

Canaccord analyst, William J. Plovanic, said, "ARTC announced it had reached a preliminary settlement agreement for its outstanding shareholder class action lawsuits for $74M. We believe investors will view this positively as it removes one of the major remaining legal headwinds for the company, leaving the DOJ as the last legal overhang."

For an analyst ratings summary and ratings history on ArthroCare click here. For more ratings news on ArthroCare click here.

Shares of ArthroCare closed at $28.47 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Teleflex (TFX) PT Raised to $170 at Needham
• Wells Fargo Downgrades Fidelity National Information Services (FIS) to Equal Weight
• Vivid Seats Inc. (SEAT) PT Raised to $7.50 at Deutsche Bank